Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase EARLY_PHASE1 1Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 13Neoplasms 12Glioma 12Prostatic Neoplasms 11Glioblastoma 11Colorectal Neoplasms 10Brain Neoplasms 10Pancreatic Neoplasms 9Neoplasm Metastasis 9Melanoma 8Lymphoma, B-Cell 8Lymphoma 8Recurrence 7Multiple Myeloma 7Carcinoma, Renal Cell 6Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Carcinoma, Non-Small-Cell Lung 5Skin Neoplasms 4Head and Neck Neoplasms 4Carcinoma, Hepatocellular 4Advanced Solid Tumors 4Solid Tumor 3Pituitary Neoplasms 3Neoplasms, Plasma Cell 3Myelodysplastic Syndromes 3Lymphoma, Follicular 3Lung Neoplasms 3Carcinoma, Transitional Cell 3

Interventions

CIMAvax EGF 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Pneumonia × 90 days × Clear all
NCT04298606 2026-03-17

A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

Roswell Park Cancer Institute

Phase EARLY_PHASE1 Completed
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pneumonia, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡